Hester Biosciences Ltd
Hester Biosciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #80 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage. Management is confident about sustaining and improving growth, particularly in the Poultry Healthcare division.
From Hester Biosciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage.
- Post Q3 FY26, regulatory approval of the H9N2 Avian Influenza vaccine positions the company well for both domestic and export growth.
- Expansion of manufacturing capacity through capitalized fill/finish facility will support scale-up of existing products and introduction of new products.
- Animal Healthcare division is expected to gain momentum in Q4 FY26 with the commencement of government immunization programs (PPR and Goat Pox) after prior delays.
- Focus on reducing dependency on tender-based revenues by increasing direct sales to commercial and export markets.
2 more points from Hester Biosciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has capitalized a fill/finish facility, effectively doubling drug product capacity.
- Remaining capital work in progress (CWIP) worth INR 182 crores is expected to be capitalized over the coming months.
- Capex is structured in phases to support scale-up across products and markets, with progressive returns as utilization increases.
- No current plans for contract manufacturing or innovator-led manufacturing; focus remains on retaining brand and exporting directly.
- The BSL-3 facility originally for COVID vaccine production is being evaluated for repurposing into an animal vaccine manufacturing facility; specifics are yet to be finalized.
2 more points from Hester Biosciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The management discussed ongoing efforts to reduce dependence on tender-based revenues and increase direct sales in both domestic and export markets.
- Institutional orders, especially in Africa, are subject to timing delays linked to government-led immunization program funding releases and rollout schedules.
- The company reported that the delay in immunization programs (like PPR and goat pox vaccines) affected Animal Health segment revenues but is expected to resume from February 2026 with improved momentum.
- Overall, the focus remains on steady execution, capacity strengthening, and building a more balanced and resilient business, implying a stable order flow aligned with these strategies.
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Guj. Themis Bio. (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hester Biosciences Ltd Q3 FY26 results?
The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage. Management is confident about sustaining and improving growth, particularly in the Poultry Healthcare division.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
The company has capitalized a fill/finish facility, effectively doubling drug product capacity.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.